Nurosene Health Inc. (8TV.F)
Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
As of 04:42PM CEST. Market open.
| Previous close | 0.1250 |
| Open | 0.1030 |
| Bid | 0.0935 x N/A |
| Ask | 0.2900 x N/A |
| Day's range | 0.0885 - 0.1030 |
| 52-week range | 0.0885 - 1.3400 |
| Volume | |
| Avg. volume | 107 |
| Market cap | 5.231M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2030 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
NUROSENE & CYCLICA PARTNER TO DEVELOP NOVEL DRUGS FOR NEURODEGENERATIVE DISEASES
Nurosene Health Inc. ("Nurosene" or the "Company") (CSE: MEND) (Frankfurt: 8TV) (OTC: MNNDF), a healthtech company focused on delivering innovative AI based technology solutions for mental performance and wellness, is partnering, via its wholly owned subsidiary NetraMark Corp. ("NetraMark"), with Cyclica Inc. ("Cyclica"), a neo-biotech with the vision to advance the most robust and sustainable drug discovery pipeline. This partnership agreement, signed February 7th, 2022, will leverage NetraHeal
© 2022 Yahoo. All rights reserved.
